FDA Approves Chewable Flea, Tick Treatment
The U.S. Food and Drug Administration approved Merck Animal Health‘s BRAVECTO, the first chewable tablets for dogs that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose.
BRAVECTO also is effective for eight weeks against Amblyomma americanum ticks.
“BRAVECTO is a breakthrough innovation that offers pet owners and veterinarians something that no other product does, the longest-lasting oral flea and tick prevention currently available,” said KJ Varma, senior vice president, research and development, Merck Animal Health. “The approval of BRAVECTO is truly a reflection of our 70-year history of innovation, research and commitment to helping shape the future of animal health, as well as our dedication to bringing novel products to market that meet the evolving needs of pet owners, customers and the industry.”
BRAVECTO is available only through veterinarians.
The active substance of BRAVECTO, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. BRAVECTO is presented as a flavored chew.
The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis as a direct result of eliminating flea infestations. The most common side effects are mild and transient gastrointestinal effects.